Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissionsoup.com..
TP53 mutation is the most frequent genetic event in head and neck squamous cell carcinoma (HNSCC), found in more than 80% of patients with human papillomavirus-negative disease. As mutations in the TP53 gene are associated with worse outcomes in HNSCC, novel therapeutic approaches are needed for patients with TP53-mutated tumors. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issues of identifying and developing clinical trials for patients with TP53 mutations. Subcommittees, or breakout groups, were tasked with developing clinical studies in both the locally advanced and recurrent and/or metastatic (R/M) disease settings as well as considering signal-seeking trial designs. A fourth breakout group was focused on identifying and standardizing biomarker integration into trial design; this information was provided to the other breakout groups prior to the meeting to aid in study development. A total of 4 concepts were prioritized to move forward for further development and implementation. This article summarizes the proceedings of the Clinical Trials Planning Meeting with the goal of developing clinical trials for patients with TP53-mutant HNSCC that can be conducted within the National Clinical Trials Network.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:114 |
|---|---|
| Enthalten in: |
Journal of the National Cancer Institute - 114(2022), 12 vom: 08. Dez., Seite 1619-1627 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodriguez, Cristina P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 14.12.2022 Date Revised 03.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/jnci/djac163 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345704525 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345704525 | ||
| 003 | DE-627 | ||
| 005 | 20231226025658.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jnci/djac163 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1152.xml |
| 035 | |a (DE-627)NLM345704525 | ||
| 035 | |a (NLM)36053203 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rodriguez, Cristina P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.12.2022 | ||
| 500 | |a Date Revised 03.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissionsoup.com. | ||
| 520 | |a TP53 mutation is the most frequent genetic event in head and neck squamous cell carcinoma (HNSCC), found in more than 80% of patients with human papillomavirus-negative disease. As mutations in the TP53 gene are associated with worse outcomes in HNSCC, novel therapeutic approaches are needed for patients with TP53-mutated tumors. The National Cancer Institute sponsored a Clinical Trials Planning Meeting to address the issues of identifying and developing clinical trials for patients with TP53 mutations. Subcommittees, or breakout groups, were tasked with developing clinical studies in both the locally advanced and recurrent and/or metastatic (R/M) disease settings as well as considering signal-seeking trial designs. A fourth breakout group was focused on identifying and standardizing biomarker integration into trial design; this information was provided to the other breakout groups prior to the meeting to aid in study development. A total of 4 concepts were prioritized to move forward for further development and implementation. This article summarizes the proceedings of the Clinical Trials Planning Meeting with the goal of developing clinical trials for patients with TP53-mutant HNSCC that can be conducted within the National Clinical Trials Network | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a TP53 protein, human |2 NLM | |
| 700 | 1 | |a Kang, Hyunseok |e verfasserin |4 aut | |
| 700 | 1 | |a Geiger, Jessica L |e verfasserin |4 aut | |
| 700 | 1 | |a Burtness, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Christine H |e verfasserin |4 aut | |
| 700 | 1 | |a Pickering, Curtis R |e verfasserin |4 aut | |
| 700 | 1 | |a Fakhry, Carole |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Quynh Thu |e verfasserin |4 aut | |
| 700 | 1 | |a Yom, Sue S |e verfasserin |4 aut | |
| 700 | 1 | |a Galloway, Thomas J |e verfasserin |4 aut | |
| 700 | 1 | |a Golemis, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Shoop, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Stuart |e verfasserin |4 aut | |
| 700 | 1 | |a Mehra, Ranee |e verfasserin |4 aut | |
| 700 | 1 | |a Skinner, Heath |e verfasserin |4 aut | |
| 700 | 1 | |a Saba, Nabil F |e verfasserin |4 aut | |
| 700 | 1 | |a Flores, Elsa R |e verfasserin |4 aut | |
| 700 | 1 | |a Myers, Jeffrey N |e verfasserin |4 aut | |
| 700 | 1 | |a Ford, James M |e verfasserin |4 aut | |
| 700 | 1 | |a Karchin, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Ferris, Robert L |e verfasserin |4 aut | |
| 700 | 1 | |a Kunos, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Lynn, Jean M |e verfasserin |4 aut | |
| 700 | 1 | |a Malik, Shakun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the National Cancer Institute |d 1945 |g 114(2022), 12 vom: 08. Dez., Seite 1619-1627 |w (DE-627)NLM000019747 |x 1460-2105 |7 nnns |
| 773 | 1 | 8 | |g volume:114 |g year:2022 |g number:12 |g day:08 |g month:12 |g pages:1619-1627 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jnci/djac163 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 114 |j 2022 |e 12 |b 08 |c 12 |h 1619-1627 | ||